NEW YORK
Suso Jersey , May 20 (Xinhua) -- Two new immune drugs for some of the deadly cancers, respectively named Keytruda and Opdivo, could help patients live years longer than those receiving older treatments, a clinical trial study said.
The study showed that Keytruda drug, a product of U.S.-based pharmaceutical company Merck & Co
Riccardo Montolivo Jersey , helped about 40 percent of patients with advanced melanoma cancer survive at least three years. Meanwhile, Bristol-Myers demonstrated that Opdivo drug can prolong life for a significant number of patients with advanced lung cancer by at least two years.
Konu Seçenekleri
